Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images

Sponsor
University Hospital Erlangen (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05110677
Collaborator
Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany (Other), Division of Computer Assisted Medical Interventions, German Cancer Research Center, Heidelberg, Germany (Other)
9
1
8.2
1.1

Study Details

Study Description

Brief Summary

The aim of this explorative pilot study is to present muscle perfusion of the lower extremity in patients with PAD using the Multispectral Optoacoustic Tomography (MSOT) method to build a 3D reconstruction of the calf muscle. This study aims to show the feasibility of 3D reconstruction of this non-invasive method. Advantages in diagnostics for patients with PAD and three-dimensional tomography representation of the perfusion situation based on muscle oxygenation will be evaluated.

Condition or Disease Intervention/Treatment Phase
  • Device: Multispectral Optoacoustic Tomography (MSOT)

Detailed Description

Functional imaging diagnostics is becoming increasingly important due to the steadily growing knowledge of physiological processes in many diseases. Also in peripheral arterial occlusive disease (PAD), new insights into the pathomechanism of the disease are continuously being gained. This also increases the need for new non-invasive imaging methods that are able to visualize the functional level of the disease progression and thus make it possible to diagnose it at an early stage.

Recent studies indicate that it may be feasible to use multispectral optoacoustic tomography (MSOT) to visualize hemodynamics as well as the fibrotic muscle remodeling process in PAD. For a better understanding of the distribution pattern , the exploration of a 3D technique is a next necessary step in imaging. This may show a possible existing heterogeneity of these molecules.

Holzwarth et al. were already able to gain knowledge about the 3D reconstruction from 2D photoacoustic image slices using an optical pattern and the method's feasibility using phantoms as well as in-vivo measurements of the forearm in healthy volunteers.

The aim of this exploratory pilot project is to bring these previous findings together and to image muscle perfusion of the lower extremity in three dimensions using the MSOT method and to verify its feasibility. The advantage of 3D imaging is, beyond the anatomical topography of the muscle, to map a three-dimensional representation of the perfusion situation based on muscle oxygenation.

For this purpose, six patients of different symptomatic PAD stages and a healthy control of two volunteers will be included and examined by means of longitudinal MSOT scans in the area of the gastrocnemius muscle. To evaluate the current stage of the disease or to exclude relevant PAD in the healthy control population, non-invasive examination measures commonly used in routine diagnostics of PAD will be applied. In addition to the relevant risk factors/adjacent diseases and the current medication intake, these include the recording of the ankle-brachial index (ABI), color-coded duplex sonographic vascular imaging (CCDS) and a treadmill examination.

Study Design

Study Type:
Observational
Actual Enrollment :
9 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Pilot Study of Topographic Imaging of the Gastrocnemius Muscle in Patients With PAD Using Non-invasive Multispectral Optoacoustic Tomography (MSOT) as a 3D Reconstruction Based on Longitudinal 2D Measurements
Actual Study Start Date :
Nov 24, 2021
Actual Primary Completion Date :
Jan 31, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Study group

Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus gastrocnemius of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site) Physical assessment: Color-Coded Duplex Sonography/treadmill examination to determine actual walking distance/Ankle-Brachial-Index/defined walking distance of 150 meters under medical supervision

Device: Multispectral Optoacoustic Tomography (MSOT)
non-invasive transcutaneous imaging of subcellular muscle components

Outcome Measures

Primary Outcome Measures

  1. MSOT topogram showing MSOT parameters from 660 up to 1100 nm of the gastrocnemius muscle [single time point (1 day)]

    MSOT topogram using 3D reconstruction based on longitudinal 2D scans trough an optical pattern showing MSOT parameters from 660 up to 1100 nm of the gastrocnemius muscle

Secondary Outcome Measures

  1. Acquisition of the quantitative hemoglobin signal (oxygenated/deoxygenated) [single time point (1 day)]

    This Outcome is measured non-invasively by MSOT, the single wavelengths are spectrally unmixed

  2. Acquisition of the quantitative fibrosis signals (collagen/lipid) [single time point (1 day)]

    This Outcome is measured non-invasively by MSOT, the single wavelengths are spectrally unmixed

  3. 3D reconstruction of the longitudinal measurements using two different pattern designs [single time point (1 day)]

    This Outcome is measured non-invasively by MSOT. A foil imprinted with an "N" is applied and fixed over the calf muscle. Three longitudinal 2D measurements are made or repeated until a promising result is obtained. The same procedure is repeated with a foil imprinted with a trident.

  4. Acquisition of static 2D MSOT measurements before and after gait exposure [single time point (1 day)]

    This Outcome is measured non-invasively by MSOT. An initial measurement is taken at rest. Subsequently, the patient will complete a defined walking distance of 150 meters under medical supervision. Afterwards, the medial head of the gastrocnemius muscle is measured again.

  5. Validation of the accuracy of the MSOT 3D reconstruction using an overlay from MRA [single time point (1 day)]

    This Outcome is only realized in participants who received an magnetic resonance angiography regardless of study participation

  6. Acquisition of the flow profile of the common femoral artery and popliteal artery using CCDS [single time point (1 day)]

    This Outcome is measured non-invasively by standardized vascular sonography

  7. Acquisition of the Ankle-Brachial-Index [single time point (1 day)]

    This Outcome is measured non-invasively by standardized clinical assessment according to the according to the recommendation from the S3 guideline for PAD of the German Association for Angiology ("Deutsche Gesellschaft für Angiologie") dated November 30, 2015

  8. Acquisition of the current walking distance standardized by treadmill examination [single time point (1 day)]

    This Outcome is measured by a standardized treadmill examination (excluding PAD patients in chronic critical stage III or IV according to Fontaine) ideally with 3km/h and 12% incline

  9. Acquisition of the PAD stage according to Fontaine and Rutherford [single time point (1 day)]

    This Outcome is acquired by actual recommendation from national and international guidelines

  10. Recording of relevant patient data from the patient's file [single time point (1 day)]

    Preexisting disorders, previous performed operations on vessels, current medication, radiological TransAtlantic InterSociety Consensus classification

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients with manifest PAD stages II-IV according to Fontaine or healthy volunteers

  • Adult (>18 years) persons who are able to give their consent

Exclusion Criteria:
  • Patients with PAD stage I according to Fontaine

  • Healthy volunteers with pre-existing diabetes mellitus, chronic renal failure, or abnormal ABI

  • Underage persons

  • Missing consent form

  • Exclusion due to safety concerns of the study physician (patient with a physical, mental or psychiatric illness which, in the opinion of the study physician, would compromise the safety of the patient or the quality of the data and thus make the patient an unsuitable candidate for the study)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Erlangen, Vascular Surgery Erlangen Germany 91054

Sponsors and Collaborators

  • University Hospital Erlangen
  • Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany
  • Division of Computer Assisted Medical Interventions, German Cancer Research Center, Heidelberg, Germany

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Ulrich Rother, PD Dr. med., University Hospital Erlangen
ClinicalTrials.gov Identifier:
NCT05110677
Other Study ID Numbers:
  • MSOT_PAD_3D
First Posted:
Nov 8, 2021
Last Update Posted:
Feb 21, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ulrich Rother, PD Dr. med., University Hospital Erlangen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2022